-transparent.png){kind=logo}
Previous studies have demonstrated an upregulation of interleukin-1 (IL-1) receptors following treatment of mouse AtT-20 pituitary tumor cells with corticotropin-releasing factor (CRF). In the present study, we determined the modulation of IL-1 receptors and adenylate cyclase activity in AtT-20 cultures following treatment with CRF, isoproterenol, forskolin, somatostatin and dexamethasone. CRF, isoproterenol and forskolin dose-dependently increased cAMP production and [125I]IL-1 alpha binding. In contrast, somatostatin and dexamethasone significantly inhibited CRF-stimulated cAMP production and decreased both basal and CRF-mediated increases in [125I]IL-1 alpha binding. Parallel modulation of IL-1 receptors by agents that stimulate (CRF, isoproterenol and forskolin) or inhibit (somatostatin) cAMP production in AtT-20 cells suggest the importance of this second messenger in regulating IL-1 receptors.
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
January 2002,
Neuroimmunomodulation,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
February 1992,
FEBS letters,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
November 1991,
Endocrinology,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
November 2000,
Pituitary,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
March 1989,
Proceedings of the National Academy of Sciences of the United States of America,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
July 1991,
Neuroscience letters,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
December 1981,
Biochemistry,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
October 1988,
The Journal of pharmacology and experimental therapeutics,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
February 1995,
Neuroscience letters,
T Takao, and
K D Dieterich, and
D E Tracey, and
E B De Souza
April 1984,
Molecular and cellular endocrinology,
